Real‐World Use, Effectiveness and Tolerability of Antidepressant Treatment in Oncology Patients
Psycho-Oncology · 2025
DOI: 10.1002/pon.70340 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Psycho-Oncology, 2025. Verfasst von Alessio Simonetti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Major Depressive Disorder, Antidepressive Agents, Neoplasms. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Depression significantly impacts quality of life and prognosis in subjects with cancer. Despite the evidence supporting the role of pharmacotherapy, real‐world data on the effectiveness and tolerability of different antidepressant classes in cancer populations remain limited.
Objective
To assess the effectiveness and tolerability of antidepressant classes and individual agents in oncology patients with major depressive disorder (MDD), and to investigate antidepressant prescription trends.
Methods
This 6‐month retrospective observational study was conducted in 170 oncology outpatients with MDD. Patients received monotherapy with tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), or a multimodal antidepressant class including only vortioxetine. Psychiatric symptoms were evaluated at baseline and after 1 and 6 months. Evaluation included rates of response, remission and changes in rating scales assessing depression, anxiety, suicidality, and agitation.
Results
All antidepressant classes showed comparable effectiveness and capability of reducing depression, anxiety, and suicidal ideation over time. Vortioxetine showed a favorable tolerability profile, with no reported adverse effects, whereas SSRIs and SNRIs had higher dropout rates due to side effects. SSRIs were the most prescribed class, followed by multimodal agents. Vortioxetine was the most frequently prescribed individual antidepressant, particularly among patients undergoing chemotherapy.
Limitations
The small sample size and the lack of stratification by cancer type limit the generalizability of the results.
Conclusion
Antidepressants were equally effective in treating depression among cancer patients. Vortioxetine emerged as a well‐tolerated and preferred option for chemotherapy patients. These findings emphasize the importance of tolerability and drug‐interaction profiles in oncology care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
- Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA.
- Department of Neurosciences, Head-Neck and Chest, Section of Psychiatry, Università Cattolica del Sacro Cuore, Rome, Italy.
- Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy.
ORCID-Profile: Alessio Simonetti, Flavia Grisoni, Giovanni Camardese
Zitieren
APA
Simonetti, A., Grisoni, F., Restaino, A., Calderoni, C., Camardese, G., Donofrio, A. M., Koukopoulos, A., Montanari, S., Janiri, D., & Sani, G. (2025). Real‐World Use, Effectiveness and Tolerability of Antidepressant Treatment in Oncology Patients. Psycho-Oncology. https://doi.org/10.1002/pon.70340
Vancouver
Simonetti A, Grisoni F, Restaino A, Calderoni C, Camardese G, Donofrio AM, et al. Real‐World Use, Effectiveness and Tolerability of Antidepressant Treatment in Oncology Patients. Psycho-Oncology. 2025. doi:10.1002/pon.70340
BibTeX
@article{Simonetti2025,
author = {Simonetti, Alessio and Grisoni, Flavia and Restaino, Antonio and Calderoni, Claudia and Camardese, Giovanni and Donofrio, Antonio Maria and Koukopoulos, Alexia and Montanari, Silvia and Janiri, Delfina and Sani, Gabriele},
title = {Real‐World Use, Effectiveness and Tolerability of Antidepressant Treatment in Oncology Patients},
journal = {Psycho-Oncology},
year = {2025},
doi = {10.1002/pon.70340}
}
EUVIMED